LYNDA DUNLOP: Open Payments
NPI 1013312206 · BLOOMFIELD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,857 in 63 payments from 11 companies in 2025. Trend: 2023 $1,882 · 2024 $816 · 2025 $1,857
Food & beverage: $1,759Education: $98
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $462 |
| ABBVIE INC. | 11 | $314 |
| Axsome Therapeutics, Inc. | 5 | $300 |
| Teva Pharmaceuticals USA, Inc. | 5 | $193 |
| Otsuka America Pharmaceutical, Inc. | 8 | $172 |
| Lundbeck LLC | 8 | $154 |
| E.R. Squibb & Sons, L.L.C. | 10 | $142 |
| Vanda Pharmaceuticals Inc. | 2 | $41 |
| TMS NeuroHealth Centers Inc. | 1 | $37 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
Products named: CAPLYTA, REXULTI, VRAYLAR, Auvelity, COBENFY, AUSTEDO XR, FANAPT, TMS NeuroHealth Centers Inc..
Industry payments across CT — which companies pay providers there.
